| Outcome Measures: |
Primary: change in 24 hour weighted mean glucose, baseline (Day -1) to Day 28 | Secondary: change in fasting plasma glucose, baseline (Day -1) to Day 28|change in plasma glucose, Day -1 and Day 28: Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast; 0.5, 1, 2, and 4 hours after starting lunch before evening meal; 0.5, 1, 2, and 4 hours after starting evening meal, baseline (Day -1) and Day 28|change in glycoalbumin, baseline (Day -1) and Day 28|change in serum insulin, Day -1 and Day 28: Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast; 0.5, 1, 2, and 4 hours after starting lunch before evening meal; 0.5, 1, 2, and 4 hours after starting evening meal, baseline (Day -1) and Day 28|change in proinsulin, baseline (Day -1) and Day 28|change in C-peptide, Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast, baseline (Day -1) and Day 28|change in PYY (pancreatic peptide YY3-36), Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast, baseline (Day -1) and Day 28|change in total GLP-1 (Glucagon-like peptide-1), baseline (Day -1) and Day 28|change in active GLP-1 (Glucagon-like peptide-1), Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast, baseline (Day -1) and Day 28|change in total GIP (Gastric inhibitory polypeptide), Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast, baseline (Day -1) and Day 28|change in total glucagon, Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast, baseline (Day -1) and Day 28|change in total total cholesterol, baseline (Day -1) to after dosing on Day 28|change in total HDL (high density lipoprotein) cholesterol, baseline (Day -1) to after dosing on Day 28|change in total LDL (low density lipoprotein) cholesterol, baseline (Day -1) to after dosing on Day 28|change in total triglyceride, baseline (Day -1) to after dosing on Day 28|number and severity of adverse events, baseline (Day -1) to after dosing on Day 28|change in derived plasma glucose AUC, change in pharmacodynamic parameters derived from plasma glucose; AUC0-24h, AUC 0-4h, AUC4-8h, AUC9-13h, baseline (Day -1) to after dosing on Day 28|change in derived serum insulin AUC, change in pharmacodynamic parameters derived from serum insulin; AUC0-24h, AUC 0-4h, AUC4-8h, AUC9-13h, baseline (Day -1) to after dosing on Day 28|change in derived C-peptide AUC, change in pharmacodynamic parameters derived from C-peptide; AUC0-4h, baseline (Day -1) to after dosing on Day 28|change in derived PYY AUC, change in pharmacodynamic parameters derived from PYY; AUC0-4h, baseline (Day -1) to after dosing on Day 28|change in derived total GLP-1 AUC, change in pharmacodynamic parameters derived from total GLP-1; AUC0-4h, baseline (Day -1) to after dosing on Day 28|change in derived active GLP-1 AUC, change in pharmacodynamic parameters derived from active GLP-1; AUC0-4h, baseline (Day -1) to after dosing on Day 28|change in derived total GIP AUC, change in pharmacodynamic parameters derived from total GIP; AUC0-4h, baseline (Day -1) to after dosing on Day 28|change in derived glucagon AUC, change in pharmacodynamic parameters derived from glucagon; AUC0-4h, baseline (Day -1) to after dosing on Day 28
|
